Cytek Biosciences reported third quarter 2026 revenue of $53.2 million, a 2% year-over-year increase that slightly exceeded analyst expectations. The company demonstrated significant progress in its profitability transition, posting a narrower-than-expected net loss of $0.05 per share and achieving its best third-quarter gross margins since 2023.

Key Highlights

  • GAAP gross margin improved by 590 basis points year-over-year to 59%, while adjusted gross margin reached 61%.
  • Total installed base grew to 4,073 instruments, adding 140 units in the quarter with Aurora Evo placements nearly doubling compared to the prior year.
  • Recurring revenue from services and reagents reached $19.1 million, now accounting for 36% of total revenue on a trailing-12-month basis.